ENGOT-OV16/NOVA

The promising potential of PARP inhibitors in ovarian cancer 3:09
The promising potential of PARP inhibitors in ovarian cancer
Jonathan Ledermann • 7 Oct 2016
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising 3:10
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising
Ursula Matulonis • 7 Oct 2016
Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial 1:14
Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial
Sven Mahner • 7 Oct 2016
Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer 2:26
Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer
Mansoor Mirza • 7 Oct 2016
Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer 1:13
Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer
Mansoor Mirza
Niraparib as maintenance for platinum-sensitive ovarian cancer – results from ENGOT-OV16/NOVA trial 1:50
Niraparib as maintenance for platinum-sensitive ovarian cancer – results from ENGOT-OV16/NOVA trial
Sven Mahner • 7 Oct 2016
NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patients 2:38
NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patients
Nicoletta Colombo • 7 Oct 2016
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals